NTRK2 and neoplasm: Herein, we identified the excellent pharmacodynamic activity, multi-target characteristics and anti-tumor effect of the compound 1D228 as a new c-Met and TRK inhibitor candidate, which significantly suppressed tumor growth in c-Met and TRKB double expression tumors.